VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition

On August3, 2017, VIVUS,Inc., or the Company, issued a press release regarding its financial results for the second quarter ended June30, 2017, a business update and certain other information. The full text of the press release concerning the foregoing is furnished herewith as Exhibit99.1.

The information in this Form8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

ExhibitNo.

Description

99.1

Press Release issued by VIVUS,Inc. dated August3, 2017.


VIVUS INC Exhibit
EX-99.1 2 a17-18841_1ex99d1.htm EX-99.1 Exhibit 99.1     VIVUS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS   CAMPBELL,…
To view the full exhibit click here

About VIVUS,INC. (NASDAQ:VVUS)

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.